Press release
Fabry Disease Pipeline and Clinical Trials Assessment (2023) | Idorsia Pharmaceuticals, Protalix, Sanofi Genzyme, Sangamo Therapeutics, 4D Molecular Therapeutics, Resverlogix Corp, and others.
Fabry Disease Pipeline
The Fabry Disease Pipeline report provides an elaborate account of the drug, encompassing its mechanism of action, Fabry Disease clinical trials studies, Fabry Disease NDA approvals (if any), and product development endeavors such as technology advancements, collaborations pertaining to Fabry Disease licensing, mergers and acquisitions, funding, designations, and other relevant details concerning the product.
To explore more information on the latest breakthroughs in the Fabry Disease Pipeline treatment landscape of the report, click here @ Fabry Disease Pipeline Outlook- https://www.delveinsight.com/report-store/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Fabry Disease Pipeline Report
• Over 18+ Fabry Disease companies are evaluating 18+ Fabry Disease pipeline therapies in various stages of development, and their anticipated acceptance in the Fabry Disease market would significantly increase market revenue.
• The leading Fabry Disease Companies are working in the market include Idorsia Pharmaceuticals, Protalix, Sanofi Genzyme, Sangamo Therapeutics, 4D Molecular Therapeutics, Resverlogix Corp, AVROBIO, Freeline Therapeutics, Ozmosis Research Inc., CellGenTech, Inc., uniQure, Codexis, Canbridge, Eleva GmbH, MP6 therapeutics, Amicus therapeutics, Sigilon Therapeutics, and others
• Promising Fabry Disease Pipeline therapies in various stages of development include Recombinant human alpha galactosidase A (agalsidase beta), Venglustat (GZ402671), Agalsidase beta (GZ419828), Migalastat, Lucerastat, and others
• Venglustat (also known as ibiglustat) (Sanofi Genzyme) is an orally administered small molecule being developed for several rare diseases. It is an inhibitor of an enzyme called glucosylceramide synthase (GCS) and modifies the enzyme substrates. GCS turns its substrate, ceramide, into glucosylceramide (GL-1) during lipid metabolism, a series of biochemical reactions that degrade and generate lipids. GL-1 acts as a substrate to other enzymes and is turned into globosides, a subclass of lipids where Gb3 belongs. When venglustat inhibits GCS, it prevents the synthesis of GL-1, thereby reducing the substrate of the following reactions that lead to the formation of Gb3 and its accumulation in the absence of α-galactosidase A. Due to this mechanism of action venglustat is called a substrate reduction therapy. The molecule is developed by Sanofi Genzyme and is in the Phase III (NCT05280548; NCT05206773) stage of development for FD. The company expects to file submission by 2025+.
Fabry Disease Overview
Fabry disease is an inherited lysosomal storage disease caused by a nonfunctional or partially functional enzyme, alpha-galactosidase A (α-Gal A). Decreased activity of α-Gal A in lysosomes results in the accumulation of enzyme substrates (Gb3 and lyso-Gb3) which cause cellular damage in tissues throughout the body.
For further information, refer to the detailed Fabry Disease Unmet Needs, Fabry Disease Market Drivers, and Fabry Disease Market Barriers, click here for Fabry Disease Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Fabry Disease Emerging Drugs Profile
• Pegunigalsidase Alfa: Protalix Biotherapeutics
• Venglustat: Sanofi
• 4D 310: 4D Molecular Therapeutics
Fabry Disease Pipeline Therapeutics Assessment
There are approx. 18+ key companies which are developing the therapies for Fabry Disease. The companies which have their Fabry Disease drug candidates in the most advanced stage, i.e. Preregistration include Protalix Biotherapeutics.
Request a sample and discover the recent advances in Fabry Disease Ongoing Clinical Trial Analysis and Medications, click here @ Fabry Disease Treatment Landscape- https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Some of the companies in the Fabry Disease Therapeutics Market include-
Idorsia Pharmaceuticals, Protalix, Sanofi Genzyme, Sangamo Therapeutics, 4D Molecular Therapeutics, Resverlogix Corp, AVROBIO, Freeline Therapeutics, Ozmosis Research Inc., CellGenTech, Inc., uniQure, Codexis, Canbridge, Eleva GmbH, MP6 therapeutics, Amicus therapeutics, Sigilon Therapeutics, and others
Fabry Disease Pipeline Therapeutics Assessment
• Fabry Disease Assessment by Product Type
• Fabry Disease by Stage and Product Type
• Fabry Disease Assessment by Route of Administration
• Fabry Disease by Stage and Route of Administration
• Fabry Disease Assessment by Molecule Type
• Fabry Disease by Stage and Molecule Type
Dive deep into rich insights for drugs for Fabry Disease Pipeline, click here @ Fabry Disease Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Fabry Disease Pipeline Report
• Coverage- Global
• Fabry Disease Companies- Idorsia Pharmaceuticals, Protalix, Sanofi Genzyme, Sangamo Therapeutics, 4D Molecular Therapeutics, Resverlogix Corp, AVROBIO, Freeline Therapeutics, Ozmosis Research Inc., CellGenTech, Inc., uniQure, Codexis, Canbridge, Eleva GmbH, MP6 therapeutics, Amicus therapeutics, Sigilon Therapeutics, and others
• Fabry Disease Pipeline Therapies- Recombinant human alpha galactosidase A (agalsidase beta), Venglustat (GZ402671), Agalsidase beta (GZ419828), Migalastat, Lucerastat, and others.
• Fabry Disease Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Fabry Disease Mergers and acquisitions, Fabry Disease Licensing Activities @ Fabry Disease Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Fabry Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Fabry Disease - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Fabry Disease Collaboration Deals
9. Late Stage Products (Preregistration)
10. Pegunigalsidase Alfa: Protalix Biotherapeutics
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Venglustat: Sanofi
14. Drug profiles in the detailed report…..
15. Early stage products (Phase I/II)
16. 4D 310: 4D Molecular Therapeutics
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Fabry Disease Key Companies
20. Fabry Disease Key Products
21. Fabry Disease- Unmet Needs
22. Fabry Disease- Market Drivers and Barriers
23. Fabry Disease- Future Perspectives and Conclusion
24. Fabry Disease Analyst Views
25. Fabry Disease Key Companies
26. Appendix
About Us
DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fabry Disease Pipeline and Clinical Trials Assessment (2023) | Idorsia Pharmaceuticals, Protalix, Sanofi Genzyme, Sangamo Therapeutics, 4D Molecular Therapeutics, Resverlogix Corp, and others. here
News-ID: 3162906 • Views: …
More Releases from DelveInsight Business Research
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Fabry
U.S. Fabry Disease Market Size Report 2034
On April 28, 2025, Exactitude Consultancy., Ltd. released a research report titled "U.S. Fabry Disease Market". This report covers the global U.S. Fabry Disease market sales, sales volume, price, market share, ranking of major companies, etc., and provides a detailed analysis by region, country, product type, and application. It also forecasts the market size of automotive kick sensors based on market patterns from 2020 to 2034 and future market trends.…
Top Factor Driving Fabry Disease Treatment Market Growth in 2025: Impact of Incr …
How Are the key drivers contributing to the expansion of the fabry disease treatment market?
The rising prevalence of renal diseases is expected to drive the growth of the Fabry disease treatment market. Renal diseases are becoming more prevalent due to genetic factors, lifestyle choices, and environmental influences. Fabry disease, which causes kidney dysfunction, is increasing and requires timely intervention. According to the Australian Bureau of Statistics, kidney disease affected 246,200…
Fabry Disease Market Trends Analysis 2030
Fabry disease is a rare X-linked lysosomal storage disorder. This patient has a deficiency in the enzyme alpha galactosidase, which progresses to organ failure. The development of fabry illnesses is mostly caused by abnormal accumulation of a certain fatty substance known as globotriaosylceramide. This aberrant buildup can be detected in the skin, eyes, heart, kidney, brain, gastrointestinal system, and central nervous system, among other body parts.
Galactosidase Alpha (GLA) is a…
Fabry Disease Market Pipeline 2019 Analysis and Developmental Stages
"Fabry Disease - Pipeline Insight, 2019” report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Fabry Disease development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued…
Fabry Disease - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape.
Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called…
Fabry Disease Market Intelligence Report Offers Growth Prospects
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of…
